PLEXBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.1 TWD | 0.00% |
|
+1.68% | -14.18% |
| Apr. 25 | PlexBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | PlexBio Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 996.8 | 1,863 | 2,424 | 1,855 | 1,249 | 1,461 |
| Enterprise Value (EV) 1 | 871.6 | 1,091 | 1,780 | 1,303 | 775.6 | 1,044 |
| P/E ratio | -4.28 x | -7.83 x | -17.2 x | -14.1 x | -23.5 x | -25.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 12.3 x | 26.2 x | 23.9 x | 14.8 x | 6.53 x | 8.74 x |
| EV / Revenue | 10.8 x | 15.3 x | 17.6 x | 10.4 x | 4.06 x | 6.25 x |
| EV / EBITDA | -4.25 x | -6.98 x | -13.4 x | -10.7 x | -13.9 x | -22.6 x |
| EV / FCF | -7.15 x | -14.8 x | -25.5 x | -47.4 x | -12.3 x | -261 x |
| FCF Yield | -14% | -6.75% | -3.92% | -2.11% | -8.15% | -0.38% |
| Price to Book | 4.14 x | 2.34 x | 3.68 x | 3.47 x | 2.61 x | 3.5 x |
| Nbr of stocks (in thousands) | 69,609 | 102,722 | 102,722 | 103,650 | 103,650 | 103,650 |
| Reference price 2 | 14.32 | 18.14 | 23.60 | 17.90 | 12.05 | 14.10 |
| Announcement Date | 4/23/19 | 4/29/20 | 4/28/21 | 4/29/22 | 4/28/23 | 4/25/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 80.99 | 71.18 | 101.3 | 124.9 | 191.2 | 167.2 |
| EBITDA 1 | -205.1 | -156.4 | -132.7 | -121.5 | -55.76 | -46.16 |
| EBIT 1 | -226.8 | -176.4 | -148.3 | -135.3 | -66.94 | -64.15 |
| Operating Margin | -280.02% | -247.82% | -146.34% | -108.26% | -35.01% | -38.37% |
| Earnings before Tax (EBT) 1 | -225.8 | -176.4 | -141.1 | -131.6 | -53.14 | -58.53 |
| Net income 1 | -225.8 | -185 | -141.1 | -131.6 | -53.14 | -58.53 |
| Net margin | -278.8% | -259.89% | -139.19% | -105.32% | -27.79% | -35.01% |
| EPS 2 | -3.345 | -2.316 | -1.369 | -1.271 | -0.5127 | -0.5600 |
| Free Cash Flow 1 | -121.9 | -73.64 | -69.75 | -27.48 | -63.19 | -4.003 |
| FCF margin | -150.49% | -103.45% | -68.82% | -21.99% | -33.05% | -2.39% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/23/19 | 4/29/20 | 4/28/21 | 4/29/22 | 4/28/23 | 4/25/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 125 | 773 | 645 | 553 | 473 | 417 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -122 | -73.6 | -69.7 | -27.5 | -63.2 | -4 |
| ROE (net income / shareholders' equity) | -138% | -35.6% | -19.3% | -22% | -10.5% | -13% |
| ROA (Net income/ Total Assets) | -55.7% | -17.8% | -10.5% | -10.9% | -6.36% | -7.3% |
| Assets 1 | 405.4 | 1,038 | 1,340 | 1,211 | 835.1 | 802 |
| Book Value Per Share 2 | 3.460 | 7.760 | 6.420 | 5.160 | 4.630 | 4.030 |
| Cash Flow per Share 2 | 1.260 | 4.350 | 3.060 | 3.360 | 2.990 | 2.650 |
| Capex 1 | 2.92 | 11.8 | 5.92 | 11.6 | 1.57 | 3.07 |
| Capex / Sales | 3.6% | 16.55% | 5.84% | 9.29% | 0.82% | 1.83% |
| Announcement Date | 4/23/19 | 4/29/20 | 4/28/21 | 4/29/22 | 4/28/23 | 4/25/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.18% | 38.45M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- 6572 Stock
- Financials PlexBio Co., Ltd.
